Myocardial Reperfusion Injury

• 

  Subject Areas on Research

  • 23Na MRI combined with contrast-enhanced 1H MRI provides in vivo characterization of infarct healing. 
  • A novel survival model of cardioplegic arrest and cardiopulmonary bypass in rats: a methodology paper. 
  • Adenosine for myocardial protection in acute myocardial infarction. 
  • Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study. 
  • Bone morphogenetic protein 4 mediates myocardial ischemic injury through JNK-dependent signaling pathway. 
  • Brain death further promotes ischemic reperfusion injury of the rabbit myocardium. 
  • Bursts of reperfusion arrhythmias occur independently of area at risk size and are the first marker of reperfusion injury. 
  • Cardiac vulnerability to ischemia/reperfusion injury drastically increases in late pregnancy. 
  • Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. 
  • Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: from animal studies to clinical trials. 
  • Chronic recurrent myocardial ischemic injury is significantly attenuated by pre-emptive adeno-associated virus heme oxygenase-1 gene delivery. 
  • Clinical perspectives on reperfusion injury in acute myocardial infarction. 
  • Commentary on selected aspects of cardioprotection. 
  • Controversies in cardiovascular MR imaging: T2-weighted imaging should not be used to delineate the area at risk in ischemic myocardial injury. 
  • Creatine kinase overexpression improves ATP kinetics and contractile function in postischemic myocardium. 
  • Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. 
  • Cytokine mRNA expression in postischemic/reperfused myocardium. 
  • Differentiation of viable and nonviable myocardium by the use of three-dimensional tagged MRI in 2-day-old reperfused canine infarcts. 
  • Double negatives. 
  • Early gene changes in myocardial ischemia. 
  • Effect of p38 MAP kinases on contractility and ischemic injury in intact heart. 
  • Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. 
  • Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. 
  • Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. 
  • Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). 
  • Gene therapy: role in myocardial protection. 
  • Getting to the heart of the matter. 
  • Heart fatty acid binding protein as a marker for postmortem detection of early myocardial damage. 
  • Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. 
  • Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. 
  • Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. 
  • Implications of ventricular arrhythmia "bursts" with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: a biosignature of direct myocellular injury "downstream of downstream". 
  • Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. 
  • Inflammation and cardiopulmonary bypass. 
  • Inflammatory gene polymorphisms and risk of postoperative myocardial infarction after cardiac surgery. 
  • Inflammatory response to cardiopulmonary bypass. 
  • Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine. 
  • Intralipid: the new magic bullet in cardioprotection? 
  • Is there a long-term predictive value of intraoperative low-dose dobutamine echocardiography in patients who have coronary artery bypass graft surgery with cardiopulmonary bypass? 
  • Ischemia promotes acyl-CoAs dephosphorylation and propionyl-CoA accumulation. 
  • Keto acid metabolites of branched-chain amino acids inhibit oxidative stress-induced necrosis and attenuate myocardial ischemia-reperfusion injury. 
  • MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury. 
  • Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. 
  • MerTK Cleavage on Resident Cardiac Macrophages Compromises Repair After Myocardial Ischemia Reperfusion Injury. 
  • Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. 
  • Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. 
  • Myocardial infarction and intramyocardial injection models in swine. 
  • Myocardial recovery after ischemia and reperfusion injury is significantly impaired in hearts with transgenic overexpression of beta-adrenergic receptor kinase. 
  • Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. 
  • Nitric oxide synthase inhibitors decrease coronary sinus-free radical concentration and ameliorate myocardial stunning in an ischemia-reperfusion model. 
  • Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. 
  • Nox1 NADPH oxidase is necessary for late but not early myocardial ischaemic preconditioning. 
  • Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. 
  • Pericardial delivery of omega-3 fatty acid: a novel approach to reducing myocardial infarct sizes and arrhythmias. 
  • Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. 
  • Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. 
  • Pharmacological therapy for myocardial reperfusion injury. 
  • Pharmacologically dosed oral glutamine reduces myocardial injury in patients undergoing cardiac surgery: a randomized pilot feasibility trial. 
  • Phenylephrine induces delayed cardioprotection against necrosis without amelioration of stunning. 
  • Physiologic effects of extracellular superoxide dismutase transgene overexpression on myocardial function after ischemia and reperfusion injury. 
  • Plasma fibronectin during myocardial ischemia-reperfusion: effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. 
  • Platelet inhibition to target reperfusion injury trial: Rationale and study design. 
  • Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. 
  • Predictors of outcome of reperfusion therapy. 
  • Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. 
  • Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. 
  • Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxyisobutyl isonitrile. 
  • Reduced reperfusion-induced Ins(1,4,5)P3 generation and arrhythmias in hearts expressing constitutively active alpha1B-adrenergic receptors. 
  • Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). 
  • Relationship of elevated 23Na magnetic resonance image intensity to infarct size after acute reperfused myocardial infarction. 
  • Reperfusion ventricular arrhythmia 'bursts' in TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction: a more precise definition of reperfusion arrhythmias. 
  • Reperfusion ventricular arrhythmia 'bursts' predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction. 
  • Report from a consensus conference on primary graft dysfunction after cardiac transplantation. 
  • Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. 
  • Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. 
  • Single dose of glutamine enhances myocardial tissue metabolism, glutathione content, and improves myocardial function after ischemia-reperfusion injury. 
  • Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. 
  • Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. 
  • The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe? 
  • The effects of dopamine on myocardial functional recovery after reversible ischemic injury. 
  • The potential of monoclonal antibodies to reduce reperfusion injury in myocardial infarction. 
  • The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? 
  • The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury. 
  • Total intravenous anesthesia and anesthetic outcomes. 
  • Untargeted metabolomics analysis of ischemia-reperfusion-injured hearts ex vivo from sedentary and exercise-trained rats. 
  • Usefulness of frequent arrhythmias after epicardial recanalization in anterior wall acute myocardial infarction as a marker of cellular injury leading to poor recovery of left ventricular function. 
  • [Serum creatine kinase isoenzyme MB and myoglobin in patients with acute myocardial infarction and coronary reperfusion]. 
• 

  Keywords of People

  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology